Eli Lilly & Co. has synthesized glucocorticoid receptor (GR) agonists reported to be useful for the treatment of atopic dermatitis and rheumatoid arthritis.
Genescience Pharmaceuticals Co. Ltd. has divulged MAP kinase-activated protein kinase 2 (MAPKAPK2; MK2) inhibitors reported to be useful for the treatment of rheumatoid arthritis and radiographic axial spondyloarthritis (ankylosing spondylitis).
The latest filing from Orlando-based Noble International Inc.—an Aptar Pharma company—hints at the development of a new category of medical devices. Best known for its medical device training solutions and patient onboarding strategies, Noble filed for protection of a compression sleeve for monitoring and treating rheumatic disorders.
Synthesis and optimization of several series of G-protein coupled receptor 183 (GPR183) antagonists at Immunophage Biomedical Co. Ltd. led to the discovery of a lead candidate with promising potency (IC50=31.3 nM), reduced hERG inhibition and improved aqueous solubility.
Rheumatoid arthritis (RA) is a systemic autoimmune disorder where Bruton tyrosine kinase (BTK) and Janus kinase 3 (JAK3) are among the most relevant signaling pathways involved.
The Korean Research Institute of Bioscience and Biotechnology has synthesized peptides reported to be useful for the treatment of inflammatory disorders.
Researchers from Seoul National University presented results of preclinical evaluation of a new TNF-α/OX40L bispecific antibody, IMB-101, being developed for the treatment of rheumatoid arthritis (RA).
The Korean Research Institute of Bioscience and Biotechnology has synthesized peptides reported to be useful for the treatment of inflammatory disorders.
Novacell Technology Inc. has identified peptides acting as N-formyl peptide receptor 2 (FPR2; FPRL1; LXA4) agonists reported to be useful for the treatment of cancer, inflammatory and immunological disorders.
Scirhom GmbH has submitted a clinical trial application (CTA) for its lead candidate, SR-878, an antibody designed to target inactive rhomboid protein 2 (iRhom2) as a therapeutic strategy for numerous autoimmune disorders.